Long-acting second-generation antipsychotics, beyond efficacy: a 12-month prospective study on patients' attitudes towards treatment

被引：0
|
作者：
Pietrini, F. [1 ]
Spadafora, M. [1 ]
Talamba, G. A. [1 ]
Godini, L. [1 ]
Santangelo, A. [1 ]
Chiarello, F. [1 ]
Ballerini, A. [1 ]
机构：
[1] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, Sect Neurosci, Florence, Italy
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷
关键词：
SCHIZOPHRENIA;
D O I：
10.1016/S0924-977X(14)70918-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.f.013
引用
收藏
页码：S573 / S574
页数：2
相关论文
共 50 条
  • [41] Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia
    Pesa, Jacqueline
    Liu, Zhiwen
    Fu, Alex Z.
    Campbell, Alicia K.
    Grucza, Richard
    SCHIZOPHRENIA RESEARCH, 2023, 261 : 170 - 177
  • [42] Clinical benefit of second-generation long-acting injectable antipsychotics in preventing re-hospitalization in patients with schizophrenia: A real-world study in Japan
    Kasahara-Kiritani, Mami
    Saga, Yosuke
    Wakamatsu, Akihide
    Wu, David Bin-Chia
    Tsai, I. -Ching
    ASIAN JOURNAL OF PSYCHIATRY, 2023, 86
  • [43] Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis
    Saucedo Uribe, Erasmo
    Carranza Navarro, Farid
    Guerrero Medrano, Andrea Fernanda
    Garcia Cervantes, Karen Iscely
    Alvarez Villalobos, Neri Alejandro
    Acuna Rocha, Victor Daniel
    Mendez Hernandez, Mauricio
    Millan Alanis, Juan Manuel
    Hinojosa Cavada, Cesar Marcelo
    Zuniga Hernandez, Jorge Alberto
    Zambrano, Stefan Mauricio Fernandez
    JOURNAL OF PSYCHIATRIC RESEARCH, 2020, 129 : 222 - 233
  • [44] Effectiveness and Predictors of Discontinuation of Aripiprazole Long-acting Injection A 12-Month Naturalistic Cohort Study
    Aftab, Romaisa
    Pereira, Marco
    Hewitt, Jed
    Whale, Richard
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2021, 41 (04) : 478 - 483
  • [45] Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics (vol 10, 931, 2020)
    Pompili, Maurizio
    FRONTIERS IN PSYCHIATRY, 2020, 11
  • [46] EXAMINING TIME TO ALL-CAUSE HOSPITALIZATION OR DEATH AMONG SECOND-GENERATION ANTIPSYCHOTICS LONG-ACTING INJECTABLES IN SCHIZOPHRENIA
    Suh, K.
    Yang, J.
    Wang, S.
    Kim, C.
    Chengappa, K. R.
    VALUE IN HEALTH, 2023, 26 (06) : S43 - S43
  • [47] Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents (vol 32, pg 241, 2018)
    Jann, Michael W.
    Penzak, Scott R.
    CNS DRUGS, 2018, 32 (06) : 603 - 603
  • [48] Second-Generation Antipsychotic Long-Acting Injection Reduced the Time of Restrictive Interventions in Patients With Schizophrenia
    Horikoshi, Sho
    Miura, Itaru
    Mui, Akihiro
    Hikichi, Takeshi
    Aono, Tetsuro
    Hoshino, Ken-yo
    Terayama, Kenji
    Yabe, Hirooki
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2022, 42 (06) : 526 - 529
  • [49] Interim-analysis of a long-term treatment study with long-acting injectable risperidone and oral second generation antipsychotics in schizophrenia
    Ibach, B.
    Schreiner, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S437 - S437
  • [50] Clinical and functioning outcomes of second-generation long-acting antipsychotics in a sample of schizophrenia patients during a follow-up period of 6 months
    Corigliano, V.
    Mancinelli, I.
    De Carolis, A.
    Tamorri, S. M.
    Di Pietro, S.
    Pazzelli, F.
    Ciccaglione, I.
    Girardi, P.
    Comparelli, A.
    EUROPEAN PSYCHIATRY, 2016, 33 : S245 - S245
12345